Xenetic Biosciences reports developments tied to its immuno-oncology programs for difficult-to-treat cancers. The company’s DNase technology targets neutrophil extracellular traps, or NETs, with a systemic DNase program being advanced as an adjunctive approach for pancreatic carcinoma and locally advanced or metastatic solid tumors.
Recurring updates include preclinical and translational research, conference presentations, collaborations with institutional and development partners, and studies evaluating DNase I with chemotherapy, immunotherapies and CAR T-cell approaches. Company news also covers periodic financial results, cash resources, equity financing, shareholder voting matters and other governance developments.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) announced the closing of a registered direct offering on December 14, 2020, selling 2,448,980 shares at $2.45 each, generating approximately $6.0 million in gross proceeds. The funds will be allocated to general corporate purposes and the advancement of the proprietary XCART technology for treating B-cell Non-Hodgkin lymphomas. The offering was conducted under a shelf registration statement with H.C. Wainwright & Co. serving as the exclusive placement agent.
Xenetic Biosciences (NASDAQ: XBIO) announced a registered direct offering of 2,448,980 shares at $2.45 each, aiming for gross proceeds of approximately $6.0 million. The funds will support general corporate purposes and the advancement of the XCART platform, focusing on personalized CAR T therapies for B-cell Non-Hodgkin lymphomas. The offering is expected to close around December 14, 2020. H.C. Wainwright & Co. is the exclusive placement agent for this transaction.
Xenetic Biosciences (NASDAQ: XBIO) announced positive results from a pivotal Phase 3 trial of Epolong, a polysialylated form of recombinant human erythropoietin. Conducted by partner Pharmsynthez, the study involved around 150 patients with chronic kidney disease. Epolong was shown to be non-inferior to Aranesp in effectiveness, with 74% of Epolong patients achieving hemoglobin targets compared to 52% for Aranesp. The results support the continued development of Epolong, which aims to reduce dosing frequency and side effects. Pharmsynthez plans to file for registration in Russia in 2021.
Xenetic Biosciences (NASDAQ:XBIO) reported on November 13, 2020, progress in advancing its XCART™ platform towards an IND filing and Phase 1 study, including a forthcoming exploratory study in Belarus targeting patients with B-cell lymphomas. The company reported a net loss of approximately $9.7 million for the first nine months of 2020, an improvement from a $11.6 million loss during the same period in 2019. As of September 30, 2020, working capital decreased to $7.2 million. The PolyXen® platform continues to generate royalties, with approximately $0.3 million received in 2020.
Xenetic Biosciences (NASDAQ: XBIO) will host a live video webcast featuring CEO Jeffrey Eisenberg on November 12, 2020, at 8:00 AM EST during the H.C. Wainwright 6th Annual Israel Conference. The event will highlight advancements in the XCART™ personalized CAR T platform, targeting tumor-specific neoantigens for B-cell lymphomas. Following the presentation, management will engage in virtual one-on-one meetings with registered investors. A replay of the webcast will be available two hours post-event and archived for 90 days.
Xenetic Biosciences (NASDAQ: XBIO) will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 12:00 PM EDT, led by CEO Jeffrey Eisenberg. The company focuses on advancing its personalized CAR T platform, XCART™, targeting tumor-specific neoantigens. After the presentation, there will be opportunities for virtual one-on-one investor meetings. A live video webcast will be accessible on the company's website, with a replay available for 90 days.
Xenetic Biosciences (NASDAQ: XBIO) reported its Q2 2020 financial results, highlighting strategic collaborations for its XCART™ CAR T therapy and advancements in PolyXen® technology. The company established partnerships with Scripps Research and Pharmsynthez, aiming to enhance clinical manufacturing and preclinical data generation. Financially, Xenetic recorded a net loss of $2.1 million, with a decrease in working capital to $8.3 million. The company has potential access to a $5 billion annual market for B-cell Non-Hodgkin lymphomas.
Xenetic Biosciences reported its Q2 2020 financial results, achieving key milestones for its differentiated CAR T therapy platform, XCART. The company established collaborations with Scripps Research and Pharmsynthez, enhancing its preclinical development capabilities. For the six months ending June 30, 2020, Xenetic posted a net loss of approximately $2.1 million, down from $2.7 million year-over-year. Working capital decreased to $8.3 million, primarily due to this loss. The company ended the quarter with about $8.1 million in cash, indicating continued investment in its promising oncology pipeline.